Orchestra BioMed Holdings, Inc.
OBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOrchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. Valued at $336.0M, OBIO is a small-cap name in its sector. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
Market Cap
$336.0M
Beta
0.52
P/E (TTM)
—
P/E (Fwd)
-3.70
EPS (TTM)
$-0.86
EPS (Fwd)
$-1.51
ROE
-397.3%
ROA
-45.7%
Cash
$110.0M
Total Debt
$70.8M
Free CF
-$31.8M
52W Change
41.5%
Annual Financials
Cash vs Debt
Where OBIO stands vs its 150-day and 200-day moving averages
As of the September 29, 2026 close, OBIO finished 32.96% above its 150-day moving average ($4.43) and 34.78% above its 200-day moving average ($4.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OBIO overbought or oversold?
At the September 29, 2026 close, OBIO's RSI(14) was 60.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $110.0M in cash comfortably exceeding the $70.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$31.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -397.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $3.5M to $33.5M.
OBIO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Orchestra BioMed Holdings, Inc.'s trajectory.